Renaissance Technologies (RenTech)'s TARA Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 125,700 shares of Protara Therapeutics, Inc. (TARA) worth $654,897, representing 0.00% of the portfolio. First purchased in 2020-Q2, this long-term strategic position has been held for 24 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained a strategic position in TARA, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2024, adding 186,340 shares. Largest reduction occurred in Q4 2024, reducing 194,440 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Protara Therapeutics (TARA) Holding Value Over Time
Track share changes against reported price movement
Quarterly Protara Therapeutics (TARA) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | -141,107 | Reduce 52.89% | 125,700 | $5.21 |
| Q4 2025 | -47,493 | Reduce 15.11% | 266,807 | $5.33 |
| Q3 2025 | +165,100 | Add 110.66% | 314,300 | $4.35 |
| Q2 2025 | +19,800 | Add 15.30% | 149,200 | $3.03 |
| Q1 2025 | -12,900 | Reduce 9.07% | 129,400 | $4.26 |
| Q4 2024 | -194,440 | Reduce 57.74% | 142,300 | $5.28 |
| Q3 2024 | +186,340 | Add 123.90% | 336,740 | $1.83 |
| Q2 2024 | +65,800 | Add 77.78% | 150,400 | $2.08 |
| Q1 2024 | -28,700 | Reduce 25.33% | 84,600 | $4.01 |
| Q4 2023 | +53,200 | Add 88.52% | 113,300 | $1.87 |
| Q3 2023 | -23,500 | Reduce 28.11% | 60,100 | $1.66 |
| Q2 2023 | +24,694 | Add 41.92% | 83,600 | $0.00 |
| Q1 2023 | -8,094 | Reduce 12.08% | 58,906 | $0.00 |
| Q4 2022 | -12,200 | Reduce 15.40% | 67,000 | $0.00 |
| Q3 2022 | +25,000 | Add 46.13% | 79,200 | $2.95 |
| Q2 2022 | +16,600 | Add 44.15% | 54,200 | $2.93 |
| Q1 2022 | -27,200 | Reduce 41.98% | 37,600 | $5.11 |
| Q4 2021 | -51,100 | Reduce 44.09% | 64,800 | $6.74 |
| Q3 2021 | +64,473 | Add 125.37% | 115,900 | $6.92 |
| Q2 2021 | +20,027 | Add 63.78% | 51,427 | $9.74 |
| Q1 2021 | +14,290 | Add 83.52% | 31,400 | $15.73 |
| Q4 2020 | -20,676 | Reduce 54.72% | 17,110 | $24.20 |
| Q3 2020 | +7,800 | Add 26.01% | 37,786 | $16.83 |
| Q2 2020 | +29,986 | New Buy | 29,986 | $29.31 |
Renaissance Technologies (RenTech)'s Protara Therapeutics Investment FAQs
Renaissance Technologies (RenTech) first purchased Protara Therapeutics, Inc. (TARA) in Q2 2020, acquiring 29,986 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Protara Therapeutics, Inc. (TARA) for 24 quarters since Q2 2020.
Renaissance Technologies (RenTech)'s largest addition to Protara Therapeutics, Inc. (TARA) was in Q3 2024, adding 336,740 shares worth $616,234.
According to the latest 13F filing for Q1 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 125,700 shares of Protara Therapeutics, Inc. (TARA), valued at approximately $654,897.
As of the Q1 2026 filing, Protara Therapeutics, Inc. (TARA) represents approximately 0.00% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Protara Therapeutics, Inc. (TARA) was 336,740 shares, as reported at the end of Q3 2024.